Begin Main Content Area

​COVID-19 Information for Providers

DDAP Guidance

Suspension of regulations

  • Licensing Alert 01-20 - 28 Pa. Code §715.16(e), which prohibits Narcotic Treatment Programs (NTPs) from allowing a patient to receive more than a 2-week take-home supply of medication.
  • Licensing Alert 02-20 - 28 Pa. Code § 715.9(a)(4), which requires Narcotic Treatment Programs (NTPs) to make a face-to-face determination before admission to treatment, for those clients who will receive buprenorphine treatment.
  • Licensing Alert 03-20 - 28 Pa. Code § 715.6(d), which requires NTPs to have narcotic treatment physician services onsite.


Practical Review of Alcohol Withdrawal Management during Coronavirus Pandemic

National Guidance and Resources

American Medical Association (AMA)
American Psychiatric Association (APA)
American Society of Addiction Medicine (ASAM)
Center for Medicare & Medicaid Services (CMS)
Drug Enforcement Agency (DEA)

National Association of Addiction Professionals (NAADAC):
National Alliance for Recovery Residences (NARR):
National Council for Behavioral Health
National Institute of Drug Abuse (NIDA)
Substance Abuse and Mental Health Services Administration (SAMHSA):
United States Department of Agriculture (USDA)
United States Department of Health and Human Services (HHS)